Loading...
Loading...
Barrington Research reiterated its Spectranetics
SPNC Outperform rating and $13 price target in a research report published today.
In the report, Barrington Research stated, "We believe there is a significant growth opportunity for SPNC's vascular intervention business as it is expected to gain more indications and more awareness over the next couple of years. SPNC has recently launched a Peripheral Artery Disease ("PAD") market awareness program. PAD has a huge addressable market of 15 million people, and only less than 15% are diagnosed or treated. We believe this program will help the company achieve its double-digit growth as time goes on."
Shares of Spectranetics closed today at $10.46, down 0.29% from Monday's market close.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in